NCT05158387: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
- State
- Completed
- Phase
- Phase 3
- People
- 1,172 taking part
- Started
- 7 Feb 2022
- Primary completion
- 19 Jan 2026
- Arms
- Tozorakimab Dose 1, Tozorakimab Dose 2
- Results
- None posted
- Papers
- doi:10.1056/nejmoa2606998, doi:10.1136/bmjresp-2026-004145
- 15 Dec 2021: Trial registered
- 7 Feb 2022: Trial started
- 22 Mar 2026: Trial completed